Retrospective analysis of gefitinib combined with carboplatin plus pemetrexed for NSCLC with activating EGFR mutations

被引：0
|
作者：
Tsurumi, K. [1 ]
Suzuki, A. [1 ]
Watanabe, K. [1 ]
Fukuhara, T. [1 ]
机构：
[1] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.415
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P39-7
引用
收藏
页码：S1378 / S1378
页数：1
相关论文
共 50 条
  • [1] Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009)
    Fukuhara, T.
    Inoue, A.
    Morita, S.
    Sugawara, S.
    Hosomi, Y.
    Ikeda, S.
    Gemma, A.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S467 - S467
  • [2] Comparative Longitudinal Toxicity Analysis of EGFR Mutated NSCLC Treated with Either Pemetrexed Carboplatin or Gefitinib
    Sharma, M.
    Patil, V.
    Joshi, A.
    Noronha, V.
    Bhattarjee, A.
    Goud, S.
    More, S.
    Ramaswamy, A.
    Karpe, A.
    Pande, N.
    Chandrasekharan, A.
    Goel, A.
    Talreja, V.
    Prabhash, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2137 - S2137
  • [3] Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
    Noronha, Vanita
    Patil, Vijay Maruti
    Joshi, Amit
    Menon, Nandini
    Chougule, Anuradha
    Mahajan, Abhishek
    Janu, Amit
    Purandare, Nilendu
    Kumar, Rajiv
    More, Sucheta
    Goud, Supriya
    Kadam, Nandkumar
    Daware, Nilesh
    Bhattacharjee, Atanu
    Shah, Srushti
    Yadav, Akanksha
    Trivedi, Vaishakhi
    Behel, Vichitra
    Dutt, Amit
    Banavali, Shripad Dinanath
    Prabhash, Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 124 - +
  • [4] The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis
    Li, Z.
    Lu, J.
    Zhao, Y.
    Guo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Phase II study of fruquintinib plus gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations
    Lu, S.
    Zhou, J.
    Niu, X.
    Chen, Y.
    Su, W.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
    Menon, N. S.
    Noronha, V.
    Chowdhury, O. Row
    Pawar, A. R.
    Patil, V. M.
    Singh, A. C.
    More, S.
    Goud, S.
    Yadav, A.
    Shah, M. J.
    Jobanputra, K. N.
    Shah, D. K.
    Prabhash, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1637 - S1637
  • [7] Phase III study of gefitinib (G) versus gefitinib plus carboplatin plus pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
    Seike, M.
    Inoue, A.
    Sugawara, S.
    Morita, S.
    Hosomi, Y.
    Ikeda, S.
    Watanabe, K.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 496 - 496
  • [8] QTWiST Analysis to Compare the Benefit of Gefitinib Versus Pemetrexed Platinum for Patients with EGFR Mutated NSCLC
    Patil, V.
    Noronha, V.
    Joshi, A.
    Goel, A.
    Talreja, V.
    Kapoor, A.
    Kumar, R.
    Mahajan, A.
    Janu, A.
    Prabhash, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2231 - S2232
  • [9] Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
    Ji, Jingran
    Aredo, Jacqueline, V
    Piper-Vallillo, Andrew
    Huppert, Laura
    Rotow, Julia K.
    Husain, Hatim
    Stewart, Susan
    Cobb, Rosemary
    Wakelee, Heather A.
    Blakely, Collin M.
    Wong, Melisa L.
    Gubens, Matthew A.
    Madani, Mohammad H.
    Digumarthy, Subba R.
    Mccoach, Caroline
    Piotrowska, Zofia
    Neal, Joel W.
    Riess, Jonathan W.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (03):
  • [10] Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation
    La Monica, Silvia
    Madeddu, Denise
    Tiseo, Marcello
    Vivo, Valentina
    Galetti, Maricla
    Cretella, Daniele
    Bonelli, Mara
    Fumarola, Claudia
    Cavazzoni, Andrea
    Falco, Angela
    Gervasi, Andrea
    Lagrasta, Costanza Annamaria
    Naldi, Nadia
    Barocelli, Elisabetta
    Ardizzoni, Andrea
    Quaini, Federico
    Petronini, Pier Giorgio
    Alfieri, Roberta
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 1051 - 1063
12345